Journal article

Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art

Zheng Quan Toh, Paul V Licciardi, James Fong, Suzanne M Garland, Sepehr N Tabrizi, Fiona M Russell, Edward K Mulholland

VACCINE | ELSEVIER SCI LTD | Published : 2015


Human papillomavirus (HPV) infection is the primary cause of genital warts, some oropharyngeal cancers and anogenital cancers, including cervical, vagina, vulvar, anal and penile cancers. Primary prevention of cervical cancer requires the prevention of high-risk HPV infections, particularly HPV genotypes 16 and 18. Both Gardasil® and Cervarix® vaccines when administered by a three-dose schedule have been demonstrated to be effective against cervical, vulva, and vaginal cancer precursors from vaccine genotypes in phase III clinical trials, and post-marketing studies; Gardasil® vaccine also offers additional protection against anal cancer precursors. However, high costs of HPV vaccines and the..

View full abstract